Molecular Basis of Angiogenesis and its Application

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology
• Ophthalmology

Background:

• Angiogenesis, or new blood vessel development, is vital physiologically but also drives diseases like cancer and wet age-related macular degeneration (AMD).
• Identifying specific regulators of angiogenesis was challenging, with many factors lacking clear pathophysiological roles.
• Vascular Endothelial Growth Factor (VEGF) was identified as a key endothelial cell mitogen and angiogenic factor.

Purpose of the Study:

• To investigate the role of VEGF in angiogenesis and its therapeutic potential.
• To develop and evaluate anti-VEGF therapies for cancer and neovascular eye diseases.

Main Methods:

• Isolation and cloning of VEGF (VEGF-A).
• Identification of VEGF receptors (VEGFR-1 and VEGFR-2).
• Development of anti-VEGF monoclonal antibodies and antibody fragments (e.g., ranibizumab).
• Preclinical studies in tumor models and clinical trials for wet AMD and cancer.

Main Results:

• VEGF is essential for vascularization, with its absence causing embryonic lethality in mice.
• Anti-VEGF antibodies effectively blocked tumor growth and neovascularization.
• Ranibizumab demonstrated significant efficacy in treating wet AMD, improving visual acuity.
• Several VEGF inhibitors are now standard treatments for various cancers and intraocular neovascularization.

Conclusions:

• VEGF is a critical regulator of angiogenesis with significant implications in disease pathogenesis.
• Anti-VEGF therapies represent a highly effective treatment strategy for angiogenesis-driven disorders.
• Ongoing research aims to optimize anti-VEGF treatments by reducing injection frequency and exploring new pathways.